Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

GeneDx Holdings Corp. - Class A Common Stock (NQ: WGS )

76.35 -1.65 (-2.12%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,267,941
Open 77.39
Bid (Size) 74.25 (1)
Ask (Size) 80.01 (10)
Prev. Close 78.00
Today's Range 74.45 - 78.49
52wk Range 4.372 - 98.87
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio?
Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%) 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga

Performance

YTD
-4.12%
-4.12%
1 Month
+11.85%
+11.85%
3 Month
+7.38%
+7.38%
6 Month
+114.89%
+114.89%
1 Year
+1411.88%
+1411.88%

More News

Read More
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
From GeneDx
Via Business Wire
Why NASDAQ:WGS qualifies as a high growth stock.
Via Chartmill
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
From GeneDx
Via Business Wire
GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
From GeneDx
Via Business Wire
GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025
From GeneDx
Via Business Wire
GeneDx: Even After Up 2,700% in 2024, Upside Is Still in Play
Via MarketBeat
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GeneDx
Via Business Wire
Stocks Moving Lower Despite Encouraging Inflation Data
Via Talk Markets
Topics Economy Stocks / Equities
Exposures Interest Rates
GeneDx Announces Preliminary 2024 Financial Results
From GeneDx
Via Business Wire
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
From GeneDx
Via Business Wire
I’m Not Worried About This Pullback
Via Talk Markets
Topics Cryptocurrencies Stocks / Equities
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
From GeneDx
Via Business Wire
IBD 50's GeneDx Surges On FDA Recommendations For AI Device Development
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Focus On High Cash Flow Companies. You Are The Company You Keep.
Via Talk Markets
Topics Stocks / Equities
Meta Stock, Energy Plays Lead Five Leaders Rebounding Bullishly
Via Investor's Business Daily
Resources Connection, SPS Commerce And 3 Stocks To Watch Heading Into Friday
Via Benzinga
GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
From GeneDx
Via Business Wire
Best Performing Stocks Of 2024
Via Talk Markets
Topics Stocks / Equities
The Top 5 Mid Cap Stocks Of 2024
Via Talk Markets
Topics Stocks / Equities
GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From GeneDx
Via Business Wire
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
From GeneDx
Via Business Wire
GeneDx to Participate in Upcoming Investor Conference
From GeneDx
Via Business Wire
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
From GeneDx
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.